SubHero Banner

Trelegy® Ellipta® (fluticasone furoate/umeclidinium/vilanterol) – Expanded indication

April 24, 2018 - GlaxoSmithKline and Innoviva announced the FDA approval of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.

Download PDF